The new FDA-approved drug was developed in order to help improve blood sugar level in patients diagnosed with type 2 diabetes.
The new drug for type 2 diabetes is called Glyxambi and is a combination of two medications: linagliptin and empagliflozin. These two medications are also manufactured by Eli Lilly and are privately owned by Boehringer.
The new drug comes in the form of a tablet that should be taken once a day.
Empagliflozin is a drug designed to prevent the kidney from reabsorbing dangerous glucose by eliminating it through urine.
Linagliptin helps by increasing the hormones that are responsible for stimulating the liver to produce a lower level of glucose. Also, linagliptin increases the number of hormones that help the pancreas with the production of more insulin.
Mike Mason, the vice president of the diabetes division at Eli Lilly, said that more than half of the people who suffer from type 2 diabetes fail to achieve the recommended blood sugar level. This means that it’s very important for patients to look at new options of treatment.
Paul Fonteyne, CEO and president of of Boehringer Ingelheim Pharmaceuticals Inc., talked about Glyxambi, saying that it’s very important to treat type 2 diabetes using multiple treatments that will help the patients achieve a normal glycemic level.
Fonteyne said in a press release that Glyxambi has proven to be very efficient in treating type 2 diabetes, because it contains the dual inhibition of SGLT2 and DPP-4.
Fonteyne explained that Glyxambi has shown to be more efficient in reducing the blood glucose levels than by using linagliption or empagliflozin separately.
Glyxambi is not recommended for patients who suffer from severe renal impairment, for patients who have an end-stage renal illness, or patients who are allergic to either empagliflozin or linagliptin.
Also, patients with type 1 diabetes or diabetic ketoacidosis should not take Glyxambi, according to researchers.
The scientists warn the patients who take Glyxambi to be very careful for any symptoms or signs of pancreatitis.
Image Source: pharmnews.net